Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 129

Results For "development"

3024 News Found

DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine
News | June 21, 2023

DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine

The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield


Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health
News | June 21, 2023

Mandaviya inaugurates G20 co-branded event of PMNCH, Geneva on health

Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency


Croda opens technical centre in Hyderabad
News | June 21, 2023

Croda opens technical centre in Hyderabad

The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.


Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
interviews | June 20, 2023

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth


Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer
Drug Approval | June 20, 2023

Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer

This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable


Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders
News | June 19, 2023

Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders

Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses


USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
Drug Approval | June 19, 2023

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma


Nanoform and Celanese demonstrate enhanced drug delivery through smaller implants
News | June 19, 2023

Nanoform and Celanese demonstrate enhanced drug delivery through smaller implants

The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.